ANTH — Anthera Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: ANTHERA PHARMA REPORTS Q3 LOSS PER SHARE $0.58
Brief: Armistice Capital reports 5.6 percent passive stake in Anthera Pharma
Brief: Anthera Pharmaceuticals announces pricing of $15 mln private placement offering
Brief: Anthera Pharma surpasses 50 pct milestone for screening of patients in result phase 3 clinical study of Sollpura in cystic fibrosis
Brief: Anthera announces top line final data from extension period of phase 2 bright-SC study of blisibimod in patients with iGa nephropathy
Brief: Anthera Pharmaceuticals announces result phase 3 clinical study of Sollpura will be included in the European cystic fibrosis clinical trial network
Brief: FDA grants orphan status to Anthera's kidney disease drug
Brief: Anthera Pharmaceuticals reports Q2 earnings per share $0.03
Brief: Anthera Pharmaceuticals announces results of Phase 3 clinical study of Sollpura
Brief: Anthera announces expansion of screening in European sites in phase 3 result clinical study of sollpura
Brief: Anthera pharmaceuticals reports qtrly loss per share $2.03
Brief: Anthera Pharmaceuticals announces 1-for-8 reverse split of stock
Brief: Anthera announces positive results from the extension period of the solution study of Sollpura
Brief: Anson Funds Management reports 6.2 pct passive stake in Anthera Pharma as of March 15
Brief: Sabby Management LLC reports 8.06 pct passive stake in Anthera Pharmaceuticals
Brief: Anthera Pharmaceuticals says public offering of 30 mln shares priced at $0.50 per share
Brief: Anthera Pharmaceuticals announces proposed public offering of common stock, warrants
New York state cyber security regulation to take effect March 1
Brief: Anthera announces the phase 3 solution study with Sollpura